Creating Value Through Breakthrough Science

Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, has announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company. Vascular Therapies plans to use the proceeds

Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations.  The round included

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round. The financing round was co-led by Ysios Capital and Forbion Growth and joined by

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing

Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, has announced that it has raised €19 million in the first close of a Series B financing, which was co-led by new investor CR-CP Life Science Fund,

VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our

BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds

Ventyx Biosciences, Inc. (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, has announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief

VORAGO Technologies (https://voragotech.com) has announced a product portfolio expansion to include a new radiation-tolerant Arm® Cortex-M0 MCU, VA10805, as a cost-competitive and high reliability solution for LEO, New Space, SmallSat and CubeSat markets. "As commercialization of space continues to grow, so does the need for reliable, affordable, and immediately available

Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis”) and Oxyrane UK Ltd (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients

Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies

Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership

Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create

Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal

Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the